drugset / Trial / NCT07812493
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and central nervous system (CNS) involvement.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2028-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 3500 mg/m2 | — |
| Subject | Pirtobrutinib | Small molecule | 200 mg | — |
| Subject | Thiotepa | Other / unclassified | 30 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |